InSite Vision, Inc.
InSite Vision, Inc.
Global collaborations in ophthalmic therapy are
setting the stage for expansion

InSite Vision, a SUN PHARMA company develops novel ophthalmic products designed to treat a growing range of common eye problems, including ocular infection, pain and inflammation in ocular surgery, and glaucoma. Our goal is to provide patients and physicians with improved treatment options that help preserve and improve vision worldwide.

Based on our DuraSite® drug delivery technology, we are creating alternative ocular anti-infective therapies, such as AzaSite Plus and AzaSite Xtra with the potential to provide significant advantages currently not available with conventional treatment options.

InSite Vision, a SUN PHARMA company is entering phase III clinical trials for AzaSite Plus, DexaSite,and BromSite.
DuraSite Technology
The proven DuraSite drug-delivery system can be customized to deliver a wide variety of novel ocular drug candidates.
Rich Pipeline
The InSite Vision portfolio includes marketed products and products in clinical development.